Oncogenic mutations in cervical cancer

Cervical cancer is the second leading cause of cancer deaths among women worldwide. The objective of this study was to describe the most common oncogenic mutations in cervical cancers and to explore genomic differences between the 2 most common histologic subtypes: adenocarcinoma and squamous cell carcinoma.

[1]  Kwok-Kin Wong,et al.  Somatic LKB1 Mutations Promote Cervical Cancer Progression , 2009, PloS one.

[2]  P. Grigsby,et al.  Pathway-Specific Analysis of Gene Expression Data Identifies the PI3K/Akt Pathway as a Novel Therapeutic Target in Cervical Cancer , 2012, Clinical Cancer Research.

[3]  George Vlachos,et al.  Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status. , 2006, Gynecologic oncology.

[4]  C. Meijer,et al.  PIK3CA-mediated PI3-kinase signalling is essential for HPV-induced transformation in vitro , 2011, Molecular Cancer.

[5]  P. Porter,et al.  Human papillomavirus and prognosis of invasive cervical cancer: a population-based study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Lee,et al.  PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers , 2011, PloS one.

[7]  Keith L. Ligon,et al.  Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples , 2009, PloS one.

[8]  M. Holden,et al.  Membranous Expression of Ectodomain Isoforms of the Epidermal Growth Factor Receptor Predicts Outcome after Chemoradiotherapy of Lymph Node–Negative Cervical Cancer , 2011, Clinical Cancer Research.

[9]  T. Burke,et al.  Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. , 1995, Gynecologic oncology.

[10]  Reiko Nishihara,et al.  Imaging , Diagnosis , Prognosis Prognostic Role of PIK 3 CA Mutation in Colorectal Cancer : Cohort Study and Literature Review , 2012 .

[11]  J. Lee,et al.  PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. , 2013, Cancer research.

[12]  M Paesmans,et al.  The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis , 2004, British Journal of Cancer.

[13]  D. Kim,et al.  Outcomes after radical hysterectomy in patients with early-stage adenocarcinoma of uterine cervix , 2010, British Journal of Cancer.

[14]  S. Yeasmin,et al.  EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target , 2011, British Journal of Cancer.

[15]  C. Ahlin,et al.  Genetic Alterations in the K-Ras Gene Influence the Prognosis in Patients With Cervical Cancer Treated by Radiotherapy , 2010, International Journal of Gynecologic Cancer.

[16]  Jason D. Wright,et al.  Prognostic significance of adenocarcinoma histology in women with cervical cancer. , 2012, Gynecologic oncology.

[17]  T. Nakano,et al.  Analysis of response to radiation therapy of patients with cervical adenocarcinoma compared with squamous cell carcinoma: MIB‐1 and PC10 labeling indices , 1996, Cancer.

[18]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[19]  Chee-Jen Chang,et al.  Role of human papillomavirus genotype in prognosis of early-stage cervical cancer undergoing primary surgery. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[21]  J. Engelman,et al.  The PI3K pathway as drug target in human cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  N. Joste,et al.  Absence of epidermal growth factor receptor mutations in cervical cancer , 2007, International Journal of Gynecologic Cancer.

[23]  A. Molven,et al.  Molecular analysis of the PI3K‐AKT pathway in uterine cervical neoplasia: Frequent PIK3CA amplification and AKT phosphorylation , 2006, International journal of cancer.

[24]  David M. Wilson,et al.  KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib. , 2013, European journal of cancer.

[25]  E. Ricevuto,et al.  Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) , 2013, BMC Medicine.

[26]  M. Sherman,et al.  Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976–2000 , 2004, Cancer.

[27]  H. Cho,et al.  HPV-18 is a poor prognostic factor, unlike the HPV viral load, in patients with stage IB-IIA cervical cancer undergoing radical hysterectomy. , 2011, Gynecologic oncology.

[28]  B. Kim,et al.  Increased expression of pAKT is associated with radiation resistance in cervical cancer , 2006, British Journal of Cancer.

[29]  J. Paramio,et al.  Molecular Signature of HPV-Induced Carcinogenesis: pRb, p53 and Gene Expression Profiling , 2009, Current genomics.

[30]  Lucio Crinò,et al.  Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. , 2013, The Lancet. Oncology.

[31]  Jeong-Won Lee,et al.  A comparison of pure adenocarcinoma and squamous cell carcinoma of the cervix after radical hysterectomy in stage IB-IIA. , 2011, Gynecologic oncology.

[32]  Enzo Medico,et al.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.

[33]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[34]  Razelle Kurzrock,et al.  PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Shiying Yu,et al.  Activated PI3K/Akt/COX-2 pathway induces resistance to radiation in human cervical cancer HeLa cells. , 2010, Cancer biotherapy & radiopharmaceuticals.

[36]  Travis J Cohoon,et al.  Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. , 2013, Cancer cell.

[37]  D. Sidransky,et al.  Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma. , 2007, Gynecologic oncology.

[38]  P. Bastiaens,et al.  Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling , 2013, Nature.

[39]  C. Wheeler,et al.  Human Papillomavirus Genotype Distributions: Implications for Vaccination and Cancer Screening in the United States , 2009, Journal of the National Cancer Institute.

[40]  W. Weichert,et al.  An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas , 2011, BMC Cancer.

[41]  M. Köbel,et al.  PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. , 2013, Gynecologic oncology.